Renibus Completes Enrollment in Phase 3 Trial of RBT-1 for Cardiac Surgery Patients
Renibus Therapeutics® has completed enrollment of 423 patients in its pivotal Phase 3 PROTECT trial, evaluating RBT-1 for reducing post-operative complications in cardiac surgery. RBT-1 is a first-in-class, single-dose preconditioning agent given 24-48 hours before surgery. Topline results are expected in Q3 2025. The FDA has granted RBT-1 both Breakthrough Therapy and Fast Track designations. 
Renibus Completes Enrollment in Phase 3 Trial of RBT-1 for Cardiac Surgery Patients